PTC Therapeutics, Inc.
2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
Last updated:
Abstract:
Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of .alpha.-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.
Status:
Grant
Type:
Utility
Filling date:
30 Mar 2021
Issue date:
16 Nov 2021